Literature DB >> 6316136

Production of secretory diarrhea by intravenous infusion of vasoactive intestinal polypeptide.

M G Kane, T M O'Dorisio, G J Krejs.   

Abstract

We attempted to reproduce the diarrhea of pancreatic cholera syndrome with prolonged (10-hour) administration of vasoactive intestinal polypeptide (VIP) in five healthy nonfasting subjects. The polypeptide was given as a continuous intravenous infusion at a rate of 400 pmol per kilogram of body weight per hour. By two hours the plasma VIP concentration had risen from a normal basal value of 15.3 +/- 0.2 (mean +/- S.E.M.) to 129 +/- 40 pmol per liter--within the range found in patients with pancreatic cholera syndrome. In each subject profuse watery diarrhea developed within 4.3 +/- 0.8 hours (range, 2.0 to 6.3), and the mean stool weight at 10 hours was 2441 +/- 600 g (normal 24-hour stool weight, less than 200 to 250 g). The results of stool analysis were consistent with secretory diarrhea. Between the first and last stool, there were significant increases in fecal sodium and bicarbonate concentrations and in pH. The large fecal bicarbonate loss induced hyperchloremic metabolic acidosis, which is characteristic in patients with pancreatic cholera syndrome. Our study suggests that VIP is not merely a marker of pancreatic cholera, but is the mediator of watery diarrhea in this syndrome.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6316136     DOI: 10.1056/NEJM198312153092403

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  18 in total

Review 1.  Aetiology of running-related gastrointestinal dysfunction. How far is the finishing line?

Authors:  S M Gil; E Yazaki; D F Evans
Journal:  Sports Med       Date:  1998-12       Impact factor: 11.136

2.  VIPoma Crisis: Immediate and life saving reduction of massive stool volumes on starting treatment with octreotide.

Authors:  Omayma Elshafie; Christopher Grant; Aisha Al-Hamdani; Rajeev Jain; Nicholas Woodhouse
Journal:  Sultan Qaboos Univ Med J       Date:  2011-02-12

3.  Effect of vasoactive intestinal peptide on cyclic adenosine monophosphate production in enterocytes isolated from human duodenal biopsy specimens.

Authors:  J A Smith; M Griffin; S E Mireylees; R G Long
Journal:  Gut       Date:  1990-12       Impact factor: 23.059

4.  Exacerbation of diarrhea after iodinated contrast agents in a patient with VIPoma.

Authors:  G S Weinstein; T M O'Dorisio; R J Joehl; B Pokorney; K L Koch
Journal:  Dig Dis Sci       Date:  1985-06       Impact factor: 3.199

5.  Pancreatic endocrine tumours associated with WDHA syndrome. An immunohistochemical and electron microscopic study.

Authors:  A Ooi; T Kameya; M Tsumuraya; K Yamaguchi; K Abe; Y Shimosato; N Yanaihara
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

6.  VIP is involved in peripheral CRF-induced stimulation of propulsive colonic motor function and diarrhea in male rats.

Authors:  Seiichi Yakabi; Lixin Wang; Hiroshi Karasawa; Pu-Qing Yuan; Kazuhiko Koike; Koji Yakabi; Yvette Taché
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-02-08       Impact factor: 4.052

7.  Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma.

Authors:  Luigi Camera; Rosa Severino; Antongiulio Faggiano; Stefania Masone; Gelsomina Mansueto; Simone Maurea; Rosa Fonti; Marco Salvatore
Journal:  World J Radiol       Date:  2014-10-28

Review 8.  Vasoactive intestinal peptide.

Authors:  S I Said
Journal:  J Endocrinol Invest       Date:  1986-04       Impact factor: 4.256

Review 9.  Is the gut an athletic organ? Digestion, absorption and exercise.

Authors:  F Brouns; E Beckers
Journal:  Sports Med       Date:  1993-04       Impact factor: 11.136

10.  Primary Pancreatic Secretinoma: Further Evidence Supporting Secretin as a Diarrheogenic Hormone.

Authors:  William Y Chey; Wendy L Frankel; Sashwati Roy; Soma Datta; Chandan K Sen; Mary Dillhoff; Peter Muscarella; Konrad H Soergel; Ronald K Tompkins; Ta-Min Chang; Edward L Bradley; Edwin Christopher Ellison
Journal:  Ann Surg       Date:  2017-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.